公开(公告)号：US20180125937A1

公开(公告)日：2018-05-10

申请号：US15621693

申请日：2017-06-13

Applicant: ModernaTX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Kristy M. WOOD ,  Sayda M. ELBASHIR ,  Noubar B. AFEYAN ,  Pedro VALENCIA ,  Jason P. SCHRUM

IPC: A61K38/19 ,  C12N15/00 ,  C12P21/00 ,  A61K9/14 ,  A61K9/127 ,  A61K38/48 ,  A61K48/00 ,  C07K14/535 ,  A61K31/7105 ,  A61K9/16 ,  A61K9/00 ,  A61K31/7088 ,  C07K2/00 ,  C12N15/117 ,  C12N15/88

CPC classification number: A61K38/193 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/0048 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K31/7088 ,  A61K31/7105 ,  A61K38/4833 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0041 ,  A61K48/005 ,  A61K48/0066 ,  C07K2/00 ,  C07K14/535 ,  C12N15/00 ,  C12N15/117 ,  C12N15/88 ,  C12P21/00

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US20180125861A1

公开(公告)日：2018-05-10

申请号：US15818089

申请日：2017-11-20

Applicant: Allergan, Inc.

Inventor： Jeffrey L. Edelman ,  Kelly M. Harrison

IPC: A61K31/573 ,  A61K31/56 ,  A61K9/16 ,  A61K31/728 ,  A61K9/00 ,  A61K47/34 ,  A61K47/36

CPC classification number: A61K31/573 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/56 ,  A61K31/728 ,  A61K47/34 ,  A61K47/36 ,  Y02A50/401

Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.

公开(公告)号：US09956177B2

公开(公告)日：2018-05-01

申请号：US14774851

申请日：2014-03-14

Applicant: OAKWOOD LABORATORIES ,  Tracy Richey ,  Bagavathikanun Chithambara Thanoo

Inventor： Tracy Richey ,  Bagavathikanun Chithambara Thanoo

IPC: A61K9/16 ,  A61K31/573

CPC classification number: A61K9/1694 ,  A61K9/1647 ,  A61K31/573

Abstract: A method of making a sustained release microsphere formulation, wherein the release rate of a bioactive ingredient is manipulated by controlling the crystallinity of said bioactive ingredient, includes the steps of combining the active ingredient and an encapsulating polymer in at least one solvent, or mixtures thereof, to form a dispersed phase and processing the dispersed phase without filtering, filtering the combined dispersed phase with a hydrophobic or a hydrophilic filter, or filtering the active ingredient and encapsulating polymer individually with a hydrophobic or hydrophilic filter before combining them to form the dispersed phase. The dispersed phase is then combined with a continuous phase to form the microsphere formulation.

公开(公告)号：US09949987B2

公开(公告)日：2018-04-24

申请号：US15459961

申请日：2017-03-15

Applicant: Flexion Therapeutics, Inc.

Inventor： Neil Bodick ,  Robert C. Blanks ,  Anjali Kumar ,  Michael D. Clayman ,  Mark Moran

IPC: A61K31/58 ,  A61K47/34 ,  A61K9/14 ,  A61K31/573 ,  A61K9/16 ,  A61K9/00

CPC classification number: A61K31/58 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/14 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/1694 ,  A61K31/573 ,  A61K47/34

Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

公开(公告)号：US09949930B2

公开(公告)日：2018-04-24

申请号：US14333584

申请日：2014-07-17

Applicant: Purdue Pharma L.P.

Inventor： Christopher Breder ,  Curtis Wright ,  Benjamin Oshlack

IPC: A61K9/20 ,  A61K9/16 ,  A61K9/50 ,  A61K31/44 ,  A61K31/445 ,  A61K31/485 ,  A61K31/46 ,  A61K45/06 ,  A61K9/14 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/2077 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/1647 ,  A61K9/167 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/2086 ,  A61K9/5026 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/44 ,  A61K31/445 ,  A61K31/46 ,  A61K31/485 ,  A61K45/06 ,  A61K47/32 ,  A61K47/38 ,  A61K2300/00

Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.

公开(公告)号：US09943483B2

公开(公告)日：2018-04-17

申请号：US15124587

申请日：2014-03-31

Applicant: PHARMATHEN S.A.

Inventor： Evangelos Karavas ,  Efthymios Koutris ,  Katerina Minioti ,  Sotiria Chaitidou ,  Georgia Papanikolaou ,  Theofanis Mantourlias

IPC: A61K9/16 ,  A61K38/31 ,  A61K9/00

CPC classification number: A61K9/1647 ,  A61K9/0019 ,  A61K9/1694 ,  A61K38/31

Abstract: A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.

公开(公告)号：US09937241B2

公开(公告)日：2018-04-10

申请号：US13651416

申请日：2012-10-13

Applicant: Sergei B Onikienko ,  Alex Nivorozhkin

Inventor： Sergei B Onikienko ,  Alex Nivorozhkin

IPC: A61K38/46 ,  A61K38/17 ,  A61K9/16 ,  A61K9/00 ,  A61K47/60

CPC classification number: A61K38/46 ,  A61K9/0075 ,  A61K9/1617 ,  A61K9/1647 ,  A61K38/1709 ,  A61K47/60

Abstract: The present invention relates to novel therapies that utilize stabilized exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of degradation resistant formulations of HSP70. Furthermore, the present invention is directed to methods comprising the administration of stabilized exogenous HSP70 for use in the treatment of HSP70 related disorders or conditions, for example, for increased endurance or alleviating fatigue syndrome.

公开(公告)号：US09937130B2

公开(公告)日：2018-04-10

申请号：US15138132

申请日：2016-04-25

Applicant: The Johns Hopkins University

Inventor： Peter J. McDonnell ,  Yasin A. Khan ,  Samuel K. Lai ,  Renata T. Kashiwabuchi ,  Ashley Behrens ,  Justin S. Hanes

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A61K31/52 ,  A61K31/519 ,  A61K45/06 ,  A61K9/51 ,  A61K47/48

CPC classification number: A61K9/1676 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/5026 ,  A61K9/5031 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/519 ,  A61K31/52 ,  A61K45/06 ,  A61K47/58 ,  A61K47/60 ,  A61K47/6921 ,  A61K47/6931

Abstract: Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.

公开(公告)号：US09931306B2

公开(公告)日：2018-04-03

申请号：US15509083

申请日：2015-09-08

Applicant: Integral Biosystems LLC

Inventor： Shikha P. Barman ,  Moli Liu ,  Koushik Barman ,  Kevin L. Ward ,  Brendan Hackett

IPC: A61K9/00 ,  A61K9/70 ,  A61K31/56 ,  A61K31/5575 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34

CPC classification number: A61K9/7007 ,  A61F9/0008 ,  A61F9/0017 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/573 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61P27/02 ,  A61P27/04 ,  A61P27/06

Abstract: A nanostructured biocompatible wafer for placement in the conjunctival cul-de-sac. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of hydrophobic polymer fibers. Also provided is a method for treating glaucoma, an ocular surface disorder, or an ocular surface infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.

公开(公告)号：US09919005B2

公开(公告)日：2018-03-20

申请号：US15341918

申请日：2016-11-02

Applicant: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.

Inventor： Daniel R. Getts

IPC: A61K9/00 ,  A61K45/00 ,  A61K31/78 ,  A61K9/14 ,  A61K9/16

CPC classification number: A61K31/78 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/146 ,  A61K9/1647 ,  A61K31/00 ,  A61K31/01 ,  A61K31/74 ,  A61K31/765 ,  A61K39/0005 ,  A61K39/001 ,  A61K39/39 ,  G01N33/6893 ,  G01N2800/7095 ,  Y02A50/394

Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.